Yes, that's the passage. My understanding is that Smiths and Morpho's competitive ETDs use "radioactive sources." If true, it suggests that since the objective of this BAA is significantly improved explosive trace detection technology and products, our two competitors would start the task well behind Implant, as they would presumably have to totally overhaul their products, perhaps even start from scratch. Implant on the other hand would only have to extend its existing, non-radioactive, technology and product line. I'm not a physicist, so there may be some wishful thinking in my perspective. Perhaps others on the board with more R&D experience can enlighten us.
